Literature DB >> 30323102

Bivalirudin fails to prevent atrial thrombus development in heparin-induced thrombocytopaenia and thrombosis syndrome.

Alexandru Topliceanu1, Thomas Breen1, Hiren Patel1, Neil Yager1, Erica Maceira2, Mikhail Torosoff1.   

Abstract

An 81-year-old woman presented with acute decompensated heart failure due to new-onset atrial fibrillation and a flail myxomatous mitral valve which necessitated surgical mitral valve repair. No atrial thrombi were noted on transoesophageal echocardiograms performed prior to surgery and intraoperatively. Immediately postoperatively, while treated with unfractionated heparin, the patient developed thrombocytopaenia with positive platelet factor 4 antibodies and an abnormal serotonin functional platelet assay, consistent with heparin-induced thrombocytopaenia. The anticoagulation therapy was changed to the direct thrombin inhibitor bivalirudin with an improvement in the platelet count. Despite bivalirudin therapy, a left atrial layering thrombus was revealed on transoesophageal echocardiogram performed in preparation for cardioversion of the symptomatic atrial fibrillation. Anticoagulation was changed to warfarin, and the patient was discharged without thromboembolic complications neither during her hospital stay nor the 3-year outpatient follow-up. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular medicine; cardiovascular system; haematology (drugs and medicines); unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2018        PMID: 30323102      PMCID: PMC6194395          DOI: 10.1136/bcr-2018-225986

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

1.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.

Authors:  Andreas Greinacher; Beate Farner; Hartmut Kroll; Thomas Kohlmann; Theodore E Warkentin; Petra Eichler
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

2.  Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.

Authors:  Andreas Koster; Cornelius M Dyke; Gabriel Aldea; Nicholas G Smedira; Harry L McCarthy; Solomon Aronson; Roland Hetzer; Edwin Avery; Bruce Spiess; A Michael Lincoff
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

3.  Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.

Authors:  Robert L Levine; Marcie J Hursting; David McCollum
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Impact of the maze procedure on the stroke rate in patients with atrial fibrillation.

Authors:  J L Cox; N Ad; T Palazzo
Journal:  J Thorac Cardiovasc Surg       Date:  1999-11       Impact factor: 5.209

6.  Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective.

Authors:  George J Palmer; Iyer S Sankaran; Gary M Sparkman; Andreas Koster; Cornelius M Dyke; George Ebra
Journal:  Heart Surg Forum       Date:  2008       Impact factor: 0.676

7.  A prospective, single-center clinical trial of a modified Cox maze procedure with bipolar radiofrequency ablation.

Authors:  Sydney L Gaynor; Michael D Diodato; Sunil M Prasad; Yosuke Ishii; Richard B Schuessler; Marci S Bailey; Nicholas R Damiano; Jeffrey B Bloch; Marc R Moon; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2004-10       Impact factor: 5.209

8.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

9.  Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.

Authors:  Abhay F Srinivasan; Lawrence Rice; John R Bartholomew; Chandhiran Rangaswamy; Lucy La Perna; James E Thompson; Scott Murphy; Kelty R Baker
Journal:  Arch Intern Med       Date:  2004-01-12

10.  An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.

Authors:  Theodore E Warkentin; Robin S Roberts; Jack Hirsh; John G Kelton
Journal:  Arch Intern Med       Date:  2003-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.